A detailed history of Met Life Investment Management, LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 47,358 shares of IDYA stock, worth $1.26 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
47,358
Previous 43,194 9.64%
Holding current value
$1.26 Million
Previous $1.52 Million 1.06%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$30.37 - $43.05 $126,460 - $179,260
4,164 Added 9.64%
47,358 $1.5 Million
Q2 2024

Aug 13, 2024

BUY
$34.37 - $43.46 $329,058 - $416,086
9,574 Added 28.48%
43,194 $1.52 Million
Q1 2024

May 14, 2024

BUY
$34.2 - $47.13 $1.15 Million - $1.58 Million
33,620 New
33,620 $1.48 Million
Q4 2023

Feb 14, 2024

BUY
$24.59 - $35.83 $73,499 - $107,095
2,989 Added 10.44%
31,632 $1.13 Million
Q3 2023

May 09, 2024

BUY
$21.07 - $29.77 $113,461 - $160,311
5,385 Added 23.15%
28,643 $772,000
Q2 2023

Apr 29, 2024

BUY
$13.33 - $25.53 $381,811 - $731,255
28,643 New
28,643 $673,000
Q2 2023

Aug 10, 2023

BUY
$13.33 - $25.53 $71,782 - $137,479
5,385 Added 23.15%
28,643 $673,000
Q1 2023

May 09, 2024

BUY
$13.49 - $18.72 $313,750 - $435,389
23,258 New
23,258 $319 Million
Q4 2022

May 10, 2024

BUY
$14.47 - $18.17 $86,631 - $108,783
5,987 Added 34.67%
23,258 $422,000
Q4 2022

Mar 22, 2023

BUY
$14.47 - $18.17 $86,631 - $108,783
5,987 Added 34.67%
23,258 $422,000
Q4 2022

Feb 15, 2023

BUY
$14.47 - $18.17 $86,631 - $108,783
5,987 Added 34.67%
23,258 $422,000
Q3 2022

Jun 14, 2023

SELL
$9.24 - $15.79 $55,319 - $94,534
-5,987 Reduced 25.74%
17,271 $257,000
Q2 2022

Jun 20, 2023

SELL
$8.28 - $13.88 $49,572 - $83,099
-5,987 Reduced 25.74%
17,271 $238,000
Q1 2022

May 10, 2024

BUY
$11.18 - $24.02 $193,089 - $414,849
17,271 New
17,271 $193,000
Q1 2022

Jun 20, 2023

SELL
$11.18 - $24.02 $66,934 - $143,807
-5,987 Reduced 25.74%
17,271 $193,000
Q1 2022

Mar 22, 2023

BUY
$11.18 - $24.02 $71,261 - $153,103
6,374 Added 58.49%
17,271 $193,000
Q1 2022

May 12, 2022

BUY
$11.18 - $24.02 $71,261 - $153,103
6,374 Added 58.49%
17,271 $193,000
Q4 2021

Jun 21, 2023

SELL
$20.95 - $26.88 $258,962 - $332,263
-12,361 Reduced 53.15%
10,897 $257,000
Q3 2021

Jun 21, 2023

SELL
$17.26 - $27.08 $213,350 - $334,735
-12,361 Reduced 53.15%
10,897 $277,000
Q2 2021

May 17, 2024

BUY
$17.76 - $24.83 $56,316 - $78,735
3,171 Added 41.04%
10,897 $228,000
Q2 2021

Jun 21, 2023

SELL
$17.76 - $24.83 $219,531 - $306,923
-12,361 Reduced 53.15%
10,897 $228,000
Q2 2021

Mar 22, 2023

BUY
$17.76 - $24.83 $56,316 - $78,735
3,171 Added 41.04%
10,897 $228,000
Q2 2021

Aug 16, 2021

BUY
$17.76 - $24.83 $56,316 - $78,735
3,171 Added 41.04%
10,897 $229,000
Q1 2021

May 17, 2024

SELL
$13.48 - $23.77 $349,051 - $615,500
-25,894 Reduced 77.02%
7,726 $181,000
Q1 2021

Jun 26, 2023

SELL
$13.48 - $23.77 $209,371 - $369,195
-15,532 Reduced 66.78%
7,726 $182 Million
Q1 2021

Mar 22, 2023

SELL
$13.48 - $23.77 $209,371 - $369,195
-15,532 Reduced 66.78%
7,726 $181,000
Q1 2021

May 14, 2021

BUY
$13.48 - $23.77 $104,146 - $183,647
7,726 New
7,726 $182,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.28B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.